The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCTX | -90.49% | N/A | N/A | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +247% |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
No news articles found for BriaCell Therapeutics.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$26.66K | 0.0% |
| Market Cap | $20.72M | -29.6% |
| Market Cap / Employee | $1.22M | 0.0% |
| Employees | 17 | -5.6% |
| Net Income | -$8,278.33K | -42.0% |
| EBITDA | -$8,296.28K | -61.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.71M | -53.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -244.43% | -130.1% |
| Return On Invested Capital | 56.34% | -51.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7,704.80K | -10.8% |
| Operating Free Cash Flow | -$7,704.80K | -10.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.11 | 2.36 | 0.79 | 1.16 | -84.08% |
| Price to Tangible Book Value | 31.48 | 38.53 | 4.00 | 1.17 | -100.14% |
| Enterprise Value to EBITDA | -1.13 | -0.57 | 0.55 | -1.18 | -62.24% |
| Return on Equity | -490.7% | -602.6% | -339.5% | -409.5% | - |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
